Resultados: 2

    Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)

    NICE is unable to make a recommendation on ciltacabtagene autoleucel (Carvykti) for treating relapsed or refractory multiple myeloma in adults. This is because Janssen withdrew its evidence submission for the appraisal. We will review this decision if the company decides to make a submission....

    Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal)

    NICE is unable to make a recommendation on teclistamab (Tecvayli) for treating relapsed or refractory multiple myeloma after 3 or more therapies in adults. This is because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission....